SCHEMBL6888873

SCHEMBL6888873

C[C@H]1CCCCN1c1c(NC(Cc2ccc(Nc3nc4ccccc4n3C)cc2)C(=O)O)c(=O)c1=O

nearest known ligand 0.43

Predicted protein targets (top 12)

geneUniProtsupporting neighboursconfidence
ITGB1 P05556 14/20 0.43
ITGA4 P13612 14/20 0.43
ALDH1A1 P00352 1/20 0.41
HSD17B10 Q99714 1/20 0.41
OPRM1 P35372 2/20 0.41
OPRD1 P41143 2/20 0.41
OPRK1 P41145 2/20 0.41
OGFRL1 Q5TC84 2/20 0.41
HDAC3 O15379 1/20 0.36
HDAC1 Q13547 1/20 0.36
HDAC10 Q969S8 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6888872 1.00 ITGB1 (0.43) ITGB1ITGA4ALDH1A1HSD17B10OPRM1
SCHEMBL7049316 0.92 NPC1 (0.39) ITGB1ITGA4ALDH1A1HSD17B10OPRM1
SCHEMBL7049320 0.92 NPC1 (0.39) ITGB1ITGA4ALDH1A1HSD17B10OPRM1
SCHEMBL6888867 0.82 NPC1 (0.43) ITGB1ITGA4OPRM1OPRK1OGFRL1
SCHEMBL6888864 0.82 NPC1 (0.43) ITGB1ITGA4OPRM1OPRK1OGFRL1
SCHEMBL7718426 0.80 ITGB1 (0.42) ITGB1ITGA4ALDH1A1HSD17B10
SCHEMBL7718421 0.80 ITGB1 (0.42) ITGB1ITGA4ALDH1A1HSD17B10
SCHEMBL7718418 0.80 ITGB1 (0.42) ITGB1ITGA4ALDH1A1HSD17B10
SCHEMBL7259048 0.79 ITGB1 (0.46) ITGB1ITGA4
SCHEMBL7259045 0.79 ITGB1 (0.46) ITGB1ITGA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6740654-B2 INHIBIT THE BINDING OF INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS, OR DISORDERS INVOLVING THE INAPPROPRIATE GROWTH OR MIGRATION OF CELLS. CELLTECH R & D LIMITED (GB) 2004-05-25 US claimed
EP-1301488-A1 SQUARIC ACID DERIVATIVES CONTAINING A BICYCLIC HETEROAROMATIC RING AS INTEGRIN ANTAGONISTS Celltech R&D Limited (GB) 2003-04-16 EP claimed
US-20020107263-A1 Squaric acid derivatives CELLTECH R&D, LTD. (GB) 2002-08-08 US claimed
WO-2002004426-A1 SQUARIC ACID DERIVATIVES CONTAINING A BICYCLIC HETEROAROMATIC RING AS INTEGRIN ANTAGONISTS CELLTECH R & D LIMITED (GB) 2002-01-17 WO claimed
US-6740654-B2 INHIBIT THE BINDING OF INTEGRINS TO THEIR LIGANDS AND ARE OF USE IN THE PROPHYLAXIS AND TREATMENT OF IMMUNE OR INFLAMMATORY DISORDERS, OR DISORDERS INVOLVING THE INAPPROPRIATE GROWTH OR MIGRATION OF CELLS. CELLTECH R & D LIMITED (GB) 2004-05-25 US disclosed
EP-1301488-A1 SQUARIC ACID DERIVATIVES CONTAINING A BICYCLIC HETEROAROMATIC RING AS INTEGRIN ANTAGONISTS Celltech R&D Limited (GB) 2003-04-16 EP disclosed
US-20020107263-A1 Squaric acid derivatives CELLTECH R&D, LTD. (GB) 2002-08-08 US disclosed
WO-2002004426-A1 SQUARIC ACID DERIVATIVES CONTAINING A BICYCLIC HETEROAROMATIC RING AS INTEGRIN ANTAGONISTS CELLTECH R & D LIMITED (GB) 2002-01-17 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020107263-A1 Squaric acid derivatives SUCNR1, ICAM1, VCAM1 ITGB1 120/4885ITGA4 448/4885ALDH1A1 410/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.